2025 Q4 -tulosraportti
Vain PDF
94 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·4 t sittenI READ THE ENTIRE COMPETITIVE LANDSCAPE MAP FOR THE FIELD. HERE IS WHAT I FOUND. 🗺️🧬 An independent industry report (EHA 2026) just mapped the entire in vivo CAR-T landscape. Let me translate what it actually says — because it's interesting for us. Point 1: The money is insane.💰 The report lists the conviction in black and white: Lilly, Merck, BMS, AstraZeneca and Roche have all bought into the field — giant after giant, billion transactions. This is not a field that's «coming». It's here, and it's consolidating right now. Point 2 — and this is key: 🎯 The report states outright that there is «modest differentiation» among most players. Almost everyone is doing the same thing: LNP + mRNA or synthetic circRNA, which provides short-lived expression. They resemble each other. And this is where Circio stands out. 👇 circVec is not just another LNP-mRNA clone. Vector-based. circRNA made inside the cell. Up to SIX MONTHS of expression where the others get days. In a field the report itself describes as full of similar players — «durable» and «differentiated» is precisely what is worth the most. Point 3: Autoimmune. 🌍 The report points out that CD19 in vivo CAR-T opens up an enormous non-oncological market — lupus, MS, rheumatism. Not a niche. Millions of patients. So: a field where giants pay billions, where most look alike — and we have the durable, differentiated angle. It's not hype. It's in the map. 🧱 We know what we own. ♟️🧱🍷Benny works to bring knowledge to the market 👏🥇 And that is very good. It is absurd that the stock is at 7.7 kr, The real price is currently at 20-24 kr
·12 t sittenAre any of circios' partners publicly listed, thanks in advance, ☺
Hi Am a shareholder in both Lytix oc Circio. Got a bit mixed up on these. It is correct that it is Lytix Biopharma that collaborates with Verrica, not Circio, sorry. 😆😀
·13 t sitten · MuokattuTraffikgene has raised 3.5 million where circio is mentioned Translated article source https://www.xunta.gal/es/notas-de-prensa/-/nova/026852/nueva-spinoff-traffikgene-apoyada-por-programa-ignicia-xunta-lanza-tecnologia Also mentioned on several Spanish sites Santiago de Compostela, July 17, 2026 TraffikGene SL, a new spin-off from the University of Santiago de Compostela (USC), has been launched in Santiago de Compostela. It received almost €500,000 in funding from the Galician regional government (Xunta de Galicia) through the Ignicia Proof of Concept program. The company was established to commercialize the technology developed over several years at the Singular Center for Research in Biological Chemistry and Molecular Materials (CIQUS), a platform that facilitates the delivery of drugs to the body's cells. The company was founded after seven years of research at this Galician research center, which is part of Xunta's network of competence centers (Red CIGUS). The research group, led by Javier Montenegro, a researcher in the Oportunius program, together with Marisa Juanes, Irene Lostalé-Seijo and Alberto Fuentes, created the new method from scratch. TraffikGene is the name of the technology they developed, which allows drugs based on genetic material to safely cross cell barriers and reach the cell's interior. This technology, simpler than other alternatives on the market, can be used for new advanced therapies. The Galician Ministry of Education, Science, Universities and Vocational Training, through the Galician Innovation Agency, considers TraffikGene a success story that demonstrates how public investments are translated into real results and how initial innovative ideas can reach the market, which is the main objective of the Ignicia Proof of Concept program. The agency's director, Carmen Cotelo, confirms that this initiative is an excellent option for transferring results from research activity. This new spin-off company recently signed its first collaboration agreement with the Norwegian biotechnology company Circio, indicating market interest. To date, TraffikGene has raised over 3.5 million euros from funding from the Galician regional government (Xunta) and various European programs.The agreement was entered into on April 29 this year..https://www.circio.com/en/circio-announces-research-collaboration-with-the-universidad-de-santiago-de-compostelas-traffikgene-project-to-advance-non-viral-circvec-delivery/
·1 päivä sittenOf all those who are skeptical and write negatively about the company, I still haven't seen any basis for their claims, which is quite interesting. 🤔 Well, time will tell. Undoubtedly the most interesting case I've seen in a very long time!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
94 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenI READ THE ENTIRE COMPETITIVE LANDSCAPE MAP FOR THE FIELD. HERE IS WHAT I FOUND. 🗺️🧬 An independent industry report (EHA 2026) just mapped the entire in vivo CAR-T landscape. Let me translate what it actually says — because it's interesting for us. Point 1: The money is insane.💰 The report lists the conviction in black and white: Lilly, Merck, BMS, AstraZeneca and Roche have all bought into the field — giant after giant, billion transactions. This is not a field that's «coming». It's here, and it's consolidating right now. Point 2 — and this is key: 🎯 The report states outright that there is «modest differentiation» among most players. Almost everyone is doing the same thing: LNP + mRNA or synthetic circRNA, which provides short-lived expression. They resemble each other. And this is where Circio stands out. 👇 circVec is not just another LNP-mRNA clone. Vector-based. circRNA made inside the cell. Up to SIX MONTHS of expression where the others get days. In a field the report itself describes as full of similar players — «durable» and «differentiated» is precisely what is worth the most. Point 3: Autoimmune. 🌍 The report points out that CD19 in vivo CAR-T opens up an enormous non-oncological market — lupus, MS, rheumatism. Not a niche. Millions of patients. So: a field where giants pay billions, where most look alike — and we have the durable, differentiated angle. It's not hype. It's in the map. 🧱 We know what we own. ♟️🧱🍷Benny works to bring knowledge to the market 👏🥇 And that is very good. It is absurd that the stock is at 7.7 kr, The real price is currently at 20-24 kr
- ·12 t sittenAre any of circios' partners publicly listed, thanks in advance, ☺Hi Am a shareholder in both Lytix oc Circio. Got a bit mixed up on these. It is correct that it is Lytix Biopharma that collaborates with Verrica, not Circio, sorry. 😆😀
- ·13 t sitten · MuokattuTraffikgene has raised 3.5 million where circio is mentioned Translated article source https://www.xunta.gal/es/notas-de-prensa/-/nova/026852/nueva-spinoff-traffikgene-apoyada-por-programa-ignicia-xunta-lanza-tecnologia Also mentioned on several Spanish sites Santiago de Compostela, July 17, 2026 TraffikGene SL, a new spin-off from the University of Santiago de Compostela (USC), has been launched in Santiago de Compostela. It received almost €500,000 in funding from the Galician regional government (Xunta de Galicia) through the Ignicia Proof of Concept program. The company was established to commercialize the technology developed over several years at the Singular Center for Research in Biological Chemistry and Molecular Materials (CIQUS), a platform that facilitates the delivery of drugs to the body's cells. The company was founded after seven years of research at this Galician research center, which is part of Xunta's network of competence centers (Red CIGUS). The research group, led by Javier Montenegro, a researcher in the Oportunius program, together with Marisa Juanes, Irene Lostalé-Seijo and Alberto Fuentes, created the new method from scratch. TraffikGene is the name of the technology they developed, which allows drugs based on genetic material to safely cross cell barriers and reach the cell's interior. This technology, simpler than other alternatives on the market, can be used for new advanced therapies. The Galician Ministry of Education, Science, Universities and Vocational Training, through the Galician Innovation Agency, considers TraffikGene a success story that demonstrates how public investments are translated into real results and how initial innovative ideas can reach the market, which is the main objective of the Ignicia Proof of Concept program. The agency's director, Carmen Cotelo, confirms that this initiative is an excellent option for transferring results from research activity. This new spin-off company recently signed its first collaboration agreement with the Norwegian biotechnology company Circio, indicating market interest. To date, TraffikGene has raised over 3.5 million euros from funding from the Galician regional government (Xunta) and various European programs.The agreement was entered into on April 29 this year..https://www.circio.com/en/circio-announces-research-collaboration-with-the-universidad-de-santiago-de-compostelas-traffikgene-project-to-advance-non-viral-circvec-delivery/
- ·1 päivä sittenOf all those who are skeptical and write negatively about the company, I still haven't seen any basis for their claims, which is quite interesting. 🤔 Well, time will tell. Undoubtedly the most interesting case I've seen in a very long time!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
94 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·4 t sittenI READ THE ENTIRE COMPETITIVE LANDSCAPE MAP FOR THE FIELD. HERE IS WHAT I FOUND. 🗺️🧬 An independent industry report (EHA 2026) just mapped the entire in vivo CAR-T landscape. Let me translate what it actually says — because it's interesting for us. Point 1: The money is insane.💰 The report lists the conviction in black and white: Lilly, Merck, BMS, AstraZeneca and Roche have all bought into the field — giant after giant, billion transactions. This is not a field that's «coming». It's here, and it's consolidating right now. Point 2 — and this is key: 🎯 The report states outright that there is «modest differentiation» among most players. Almost everyone is doing the same thing: LNP + mRNA or synthetic circRNA, which provides short-lived expression. They resemble each other. And this is where Circio stands out. 👇 circVec is not just another LNP-mRNA clone. Vector-based. circRNA made inside the cell. Up to SIX MONTHS of expression where the others get days. In a field the report itself describes as full of similar players — «durable» and «differentiated» is precisely what is worth the most. Point 3: Autoimmune. 🌍 The report points out that CD19 in vivo CAR-T opens up an enormous non-oncological market — lupus, MS, rheumatism. Not a niche. Millions of patients. So: a field where giants pay billions, where most look alike — and we have the durable, differentiated angle. It's not hype. It's in the map. 🧱 We know what we own. ♟️🧱🍷Benny works to bring knowledge to the market 👏🥇 And that is very good. It is absurd that the stock is at 7.7 kr, The real price is currently at 20-24 kr
- ·12 t sittenAre any of circios' partners publicly listed, thanks in advance, ☺Hi Am a shareholder in both Lytix oc Circio. Got a bit mixed up on these. It is correct that it is Lytix Biopharma that collaborates with Verrica, not Circio, sorry. 😆😀
- ·13 t sitten · MuokattuTraffikgene has raised 3.5 million where circio is mentioned Translated article source https://www.xunta.gal/es/notas-de-prensa/-/nova/026852/nueva-spinoff-traffikgene-apoyada-por-programa-ignicia-xunta-lanza-tecnologia Also mentioned on several Spanish sites Santiago de Compostela, July 17, 2026 TraffikGene SL, a new spin-off from the University of Santiago de Compostela (USC), has been launched in Santiago de Compostela. It received almost €500,000 in funding from the Galician regional government (Xunta de Galicia) through the Ignicia Proof of Concept program. The company was established to commercialize the technology developed over several years at the Singular Center for Research in Biological Chemistry and Molecular Materials (CIQUS), a platform that facilitates the delivery of drugs to the body's cells. The company was founded after seven years of research at this Galician research center, which is part of Xunta's network of competence centers (Red CIGUS). The research group, led by Javier Montenegro, a researcher in the Oportunius program, together with Marisa Juanes, Irene Lostalé-Seijo and Alberto Fuentes, created the new method from scratch. TraffikGene is the name of the technology they developed, which allows drugs based on genetic material to safely cross cell barriers and reach the cell's interior. This technology, simpler than other alternatives on the market, can be used for new advanced therapies. The Galician Ministry of Education, Science, Universities and Vocational Training, through the Galician Innovation Agency, considers TraffikGene a success story that demonstrates how public investments are translated into real results and how initial innovative ideas can reach the market, which is the main objective of the Ignicia Proof of Concept program. The agency's director, Carmen Cotelo, confirms that this initiative is an excellent option for transferring results from research activity. This new spin-off company recently signed its first collaboration agreement with the Norwegian biotechnology company Circio, indicating market interest. To date, TraffikGene has raised over 3.5 million euros from funding from the Galician regional government (Xunta) and various European programs.The agreement was entered into on April 29 this year..https://www.circio.com/en/circio-announces-research-collaboration-with-the-universidad-de-santiago-de-compostelas-traffikgene-project-to-advance-non-viral-circvec-delivery/
- ·1 päivä sittenOf all those who are skeptical and write negatively about the company, I still haven't seen any basis for their claims, which is quite interesting. 🤔 Well, time will tell. Undoubtedly the most interesting case I've seen in a very long time!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt